Daily Cardiology Research Analysis
Three impactful cardiology studies stand out today: a meta-analysis of 23 randomized trials shows SGLT2 inhibitors reduce ventricular arrhythmias and sudden cardiac death; a 410,177-participant genetic study indicates lipoprotein(a)-related myocardial infarction risk is not mediated by prothrombotic pathways; and a novel multiparametric right ventricular-pulmonary artery coupling metric using 3D echocardiography improves mortality prediction after transcatheter tricuspid repair.
Summary
Three impactful cardiology studies stand out today: a meta-analysis of 23 randomized trials shows SGLT2 inhibitors reduce ventricular arrhythmias and sudden cardiac death; a 410,177-participant genetic study indicates lipoprotein(a)-related myocardial infarction risk is not mediated by prothrombotic pathways; and a novel multiparametric right ventricular-pulmonary artery coupling metric using 3D echocardiography improves mortality prediction after transcatheter tricuspid repair.
Research Themes
- Antiarrhythmic benefits of SGLT2 inhibitors across heart failure phenotypes
- Mechanistic role of lipoprotein(a) in myocardial infarction risk beyond thrombosis
- Advanced 3D echocardiographic metrics for right ventricular function in tricuspid intervention
Selected Articles
1. Redefining outcomes of ventricular arrhythmia for SGLT2 inhibitor medication in heart failure patients: a meta-analysis of randomized controlled trials.
This PROSPERO-registered meta-analysis of 23 RCTs (n=74,380) found SGLT2 inhibitors significantly reduce ventricular arrhythmias (RR 0.85) and sudden cardiac death (RR 0.79). Benefits persisted with ≥1-year follow-up and across HF phenotypes and related cardiometabolic conditions.
Impact: Demonstrating arrhythmic benefits of SGLT2 inhibitors extends their utility beyond heart failure hospitalization and mortality endpoints and may reshape risk-reduction strategies for VA and SCD.
Clinical Implications: Clinicians can consider SGLT2 inhibitors as part of a comprehensive strategy to reduce VA/SCD risk across HF phenotypes, while awaiting dedicated arrhythmia-focused trials. This supports early initiation in eligible HF patients.
Key Findings
- Across 23 RCTs (n=74,380), SGLT2 inhibitors reduced ventricular arrhythmias (RR 0.85, 95% CI 0.74–0.98).
- SGLT2 inhibitors reduced sudden cardiac death (RR 0.79, 95% CI 0.64–0.98).
- Benefits persisted with ≥1-year follow-up and across T2D, CVD, HFrEF, HFpEF, and HFmrEF subgroups.
Methodological Strengths
- PRISMA-guided, PROSPERO-registered meta-analysis with exclusively randomized trials
- Large aggregate sample size with prespecified subgroup analyses and long follow-up windows (12–296 weeks)
Limitations
- Arrhythmia outcomes were not primary endpoints in most included trials, risking event ascertainment variability
- Clinical heterogeneity across populations, agents, and follow-up durations
Future Directions: Conduct dedicated RCTs with arrhythmia and SCD as primary endpoints, and mechanistic studies to delineate antiarrhythmic pathways of SGLT2 inhibitors.
BACKGROUND: Sodium-glucose co-transporter 2 (SGLT2) inhibitors have been shown to lower the risk of re-hospitalization and cardiovascular mortality among heart failure (HF) patients. Nevertheless, the impact of these agents on ventricular arrhythmias (VAs) has not been thoroughly investigated. To assess the beneficial impact of SGLT2 inhibitors on VAs in patients at various stages of HF, a systematic review and meta-analysis of randomized controlled trials involving SGLT2 inhibitors in this patient population was performed. METHODS: A comprehensive search of the PubMed, Embase, Ovid, ProQuest, Scopus, and Cochrane databases was performed for clinical trials published up to November 21, 2024. The primary outcomes of interest were incidences of VAs and sudden cardiac death (SCD) between the groups receiving SGLT2 inhibitors and the control drugs. For the outcomes observed in the populations of the included trials and in specific subgroups, hazard ratios (HRs) and 95% confidence intervals (CIs) were pooled and meta-analysed across the analyses. RESULTS: A total of 23 randomized trials (22 placebo-controlled trials and 1 active-controlled trial) involving 74,380 patients (37,372 receiving SGLT2 inhibitors and 37,008 in the control group) were included. The analysed SGLT2 inhibitors included canagliflozin, dapagliflozin, empagliflozin, bexagliflozin, sotagliflozin, and ertugliflozin. The participants were non-advanced HF patients, including at-risk for HF, pre-HF, and symptomatic HF, with follow-up duration ranging from 12 to 296 weeks. Compared with the control, treatment with SGLT2 inhibitors was associated with significantly reduced risk of VAs (risk ratio (RR) 0.85, 95% confidence interval (CI) 0.74-0.98; P = 0.02) and SCD (RR 0.79, 95% CI 0.64-0.98; P = 0.03). Subgroup analyses indicated that longer follow-up (≥ 1 year) taking SGLT2 inhibitors can still reduce the risk of VAs (RR 0.79, 95% CI 0.65-0.96; P = 0.02) and SCD (RR 0.80, 95% CI 0.65-0.99; P = 0.04). CONCLUSION: SGLT2 inhibitors have beneficial effects on lowering risks of VAs and SCD in patients with type 2 diabetes, cardiovascular diseases, heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF), and heart failure with mildly reduced ejection fraction (HFmrEF), with longer follow-up duration reinforcing these findings. However, future prospective trials are needed to verify the effects of SGLT2 inhibitors on VAs and SCD. SYSTEMATIC REVIEW REGISTRATION: PROSPERO (CRD42024601914).
2. Lipoprotein(a) and prothrombotic effects: Evidence from a genetic association study.
In 410,177 UK Biobank participants, higher Lp(a) strongly increased MI risk (HR 1.31 per 100 nmol/L) but was not associated with VTE. The MI association was not modified by genetic scores for thrombin or platelet pathway activity, arguing against a prothrombotic mechanism.
Impact: This large genetic-epidemiologic analysis refines pathophysiologic understanding of Lp(a), shifting focus from thrombosis to atherogenesis and informing therapeutic targeting.
Clinical Implications: Lp(a)-driven MI risk likely reflects atherosclerotic mechanisms; intensifying antithrombotic therapy alone is unlikely to mitigate risk. These data support prioritizing Lp(a)-lowering therapies and do not support anticoagulation solely for elevated Lp(a).
Key Findings
- Higher Lp(a) was not associated with incident VTE (HR 1.02 per 100 nmol/L; p=0.13).
- Higher Lp(a) was strongly associated with incident MI (HR 1.31 per 100 nmol/L; p<0.001).
- Associations of LPA variants/Lp(a) with MI were not modified by F2/F5 (thrombin) or GUCY1A3 (platelet) genetic scores.
Methodological Strengths
- Very large prospective cohort (n=410,177) with both genetic instruments and measured Lp(a)
- Stratified analyses by thrombin and platelet pathway genetic scores to probe mechanisms
Limitations
- Observational design cannot fully exclude residual confounding
- Generalizability may be limited by UK Biobank demographics and ancestry composition
Future Directions: Evaluate whether Lp(a)-lowering therapies reduce MI independent of antithrombotic strategies and clarify atherogenic pathways (e.g., oxidized phospholipids) mediating risk.
BACKGROUND: It is unknown whether lipoprotein(a) [Lp(a)] has prothrombotic effects contributing to its association with the risk of myocardial infarction (MI). METHODS: In 410,177 participants of UK Biobank, associations of LPA genetic variants and observed Lp(a) concentrations with the risk of venous thromboembolism (VTE) and MI were investigated, stratified by scores of genetic variants influencing coagulation through the thrombin and platelet pathways (denoted as F2/F5 and GUCY1A3 scores, respectively). Risk estimates are expressed as hazard ratio (HR) and 95% confidence interval (95% CI). RESULTS: Neither LPA genetic variants nor observed Lp(a) concentration were associated with the risk of incident VTE (HR per 100 nmol/L higher Lp(a) 1.02, 95% CI 1.00-1.04, p=0.13). In contrast, there was a strong association with the risk of incident MI (HR per 100 nmol/L higher Lp(a) 1.31, 95% CI 1.29-1.33, p<0.001). The F2/F5 score was associated with a stepwise decrease in the risk of VTE, and the GUCY1A3 score with a stepwise decrease in the risk of MI. However, the associations of LPA genetic variants and observed Lp(a) concentrations with the risk of MI were not modified by stratification for either of the coagulation scores. CONCLUSION: The association between Lp(a) and MI was not modified by genetically determined levels of coagulation activity through the thrombin or platelet pathway. Our findings do not support the notion that the increased risk of MI caused by elevated Lp(a) is due to prothrombotic effects.
3. Beyond 2-Dimensional Echocardiography: A Novel Multiparametric Assessment of Right Ventricular Dysfunction in Transcatheter Tricuspid Valve Repair.
In 262 T-TEER patients with complete 3D RV echocardiography, higher 3D-RVEDV (HR 1.85) and worse RV free-wall longitudinal strain (HR 1.73) predicted 1-year mortality. A novel RVPA coupling metric that integrates function, volume, and pressure load outperformed traditional measures for survival prediction.
Impact: By integrating 3D volumetrics, strain, and pressure load, this study proposes a practical, physiologically grounded metric that improves risk stratification for T-TEER candidates.
Clinical Implications: Incorporating 3D RV volumes and RV free-wall strain into preprocedural assessment may refine patient selection and timing for T-TEER and guide optimization of right-sided heart failure management.
Key Findings
- 3D-RVEDV independently predicted 1-year mortality (HR 1.85; 95% CI 1.10–3.12; P=0.020).
- RV free-wall longitudinal strain independently predicted 1-year mortality (HR 1.73; 95% CI 1.02–2.92; P=0.042).
- A novel RVPA coupling metric integrating function, volume, and pressure stress improved survival prediction after T-TEER.
Methodological Strengths
- Use of comprehensive 3D RV echocardiography and deformation imaging in a real-world T-TEER cohort
- Time-to-event analyses with multivariable adjustment for mortality
Limitations
- Observational design without external validation limits generalizability
- Echocardiographic sPAP estimation and single-center/registry constraints may introduce measurement and selection biases
Future Directions: External validation and prospective studies to test clinical utility in decision-making, and integration with invasive hemodynamics and outcomes-based thresholds.
BACKGROUND: Right ventricular (RV) heart failure as assessed by RV to pulmonary artery coupling (RVPAc) is a prognostic marker in transcatheter tricuspid valve repair (T-TEER). However, quantification of RVPAc components by 2-dimensional (2D) echocardiography in patients with severe tricuspid regurgitation (TR) has significant limitations, and the traditional RVPAc parameter neglects the degree of volume overload/dilatation of the RV, which is another key clinical indicator for right ventricular dysfunction (RVD). Therefore, we aimed to assess RVD by a novel RVPAc parameter, including the 3 important drivers of RVD, for an improved prediction of 1-year mortality after T-TEER. METHODS: We analyzed 262 patients undergoing T-TEER with complete 3D RV echocardiography and 1-year follow-up. RESULTS: Increased 3D-RV end diastolic volume (3D-RVEDV: hazard ratio [HR], 1.85; 1.10-3.12; P = 0.020) and impaired RV free-wall longitudinal strain (RVFWLS: HR, 1.73, 1.02-2.92; P = 0.042) predicted 1-year mortality. A novel RVPAc parameter (RVFWLS/[3D-RVEDV∗sPAP CONCLUSIONS: The novel RVPAc parameter, integrating RV function, volume stress, and pressure stress is a powerful metric for RV failure and a superior predictor for survival post-T-TEER. CLINICAL TRIAL REGISTRATION: Data is based on the EveryValve Registry (ethical code number: 19-840). No further clinical Trial registration.